IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2

Off #MRK, Corporate News, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Pharmaceuticals, Research and Development News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J. & NEW YORK

New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate

KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19.

Language:
English

Contact:

Merck Media:
Patrick Ryan
+1 (201) 452-2409

Imraan Munshi
+1 (267) 884-1358

Merck Investors:
Peter Dannenbaum
+1 (908) 740-1037

Michael DeCarbo
+1 (908) 740-1807

IAVI Media:
Karie Youngdahl
+1 (212) 847-1051
[email protected]

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2 »

About The Author